Published in Contraception on October 28, 2015
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women | NCT00074425
An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS (2016) 0.88
Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals? AIDS (2016) 0.78
Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. J Acquir Immune Defic Syndr (2017) 0.76
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology (2000) 15.40
Constructing inverse probability weights for marginal structural models. Am J Epidemiol (2008) 12.39
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Contraceptive failure in the United States. Contraception (2011) 6.23
Hormonal contraception and the risk of HIV acquisition. AIDS (2007) 5.05
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Contraception and health. Lancet (2012) 3.73
Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis (1998) 2.96
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis (2013) 2.70
Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS (2007) 2.44
Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis (2015) 2.40
Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS (2010) 2.23
Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol (2001) 1.95
Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception (2014) 1.65
Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med (2015) 1.61
Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS (2012) 1.41
Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches. AIDS (2013) 1.34
The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS (2012) 1.26
Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol (2009) 1.26
Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS (2013) 1.25
Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS (2004) 1.19
Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod (2014) 0.98
Hormonal contraception and HIV risk: evaluating marginal-structural-model assumptions. Epidemiology (2011) 0.80
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Stat Commun Infect Dis (2017) 0.75